Vir Biotechnology, Inc. (VIR) has already been able to initiate its late-stage ECLIPSE program, which is using the combination of monoclonal antibody tobevibart in combination with small interfering ...

A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely ...